Transcode Therapeutics Inc (RNAZ) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.72 (+0.00%), Market cap $0.01B, 52-week low–high $6.44 ~ $15.23.
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-R
Financial statements, price targets, institutional (13F) holdings and related news for Transcode Therapeutics Inc are updated in real time on BlackAll Trade.
Transcode Therapeutics Inc trades at $1.72 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Transcode Therapeutics Inc has a market cap of about $0.01B.
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises